Neuphoria Therapeutics (NEUP) Net Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) posted quarterly Net Margin of 16888.35% for Q2 2025, up 22393.48% quarter-over-quarter from 75.08% in Q1 2025.

Neuphoria Therapeutics (NEUP) Net Margin (2024 - 2025) Analysis & Trends

Neuphoria Therapeutics (NEUP) has reported Net Margin for 2 consecutive years, with 16888.35% the latest figure, recorded in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.23%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	31.16%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-16.51%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	Neuphoria Therapeutics	21.28 Mn	1.84 Mn	-	-

Download Data